Literature DB >> 17825324

Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome with stroke-like imaging presentation: clinical, biochemical and molecular analysis.

Zuhair N Al-Hassnan1, Mohamed S Rashed, Osama Y Al-Dirbashi, Zoltan Patay, Zuhair Rahbeeni, Khaled K Abu-Amero.   

Abstract

Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome is an autosomal recessive disorder caused by mutations in ORNT1 gene that encodes a mitochondrial ornithine transporter. It has variable clinical presentations with episodic hyperammonemia, liver dysfunction, and chronic neurological manifestations. In this work, we report the findings of HHH syndrome in 3 Saudi siblings. The 4-year-old proband presented with recurrent Reye-like episodes, hypotonia, and multiple stroke-like lesions on brain MRI. Biochemical and molecular analysis confirmed that she had HHH syndrome. She significantly improved on protein restriction and sodium benzoate. Her two older siblings have milder phenotypes with protein intolerance and learning problems. In comparison to their sister, their homocitrulline and orotic acid were only mildly elevated even before treatment. The three patients were homozygous for a novel mutation in ORNT1 with a Gly220Arg change. In view of the CNS lesions, which initially were felt to be suggestive of MELAS, we sequenced the entire mtDNA genome and no potential pathogenic mutations were detected. Analysis of ORNT2 did not provide explanation of the clinical and biochemical variability. This work presents a yet unreported CNS involvement pattern, notably multiple supratentorial stroke-like lesions in association with HHH syndrome. Moreover, it illustrates considerable clinical/biochemical correlation, and describes a novel mutation. We suggest including HHH syndrome in the differential diagnosis of patients found to have stroke-like lesions on brain MRI.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17825324     DOI: 10.1016/j.jns.2007.08.003

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  12 in total

Review 1.  [Cerebral CT and MRI in mitchondrial disorders].

Authors:  J Finsterer
Journal:  Nervenarzt       Date:  2009-06       Impact factor: 1.214

2.  Ornithine and Homocitrulline Impair Mitochondrial Function, Decrease Antioxidant Defenses and Induce Cell Death in Menadione-Stressed Rat Cortical Astrocytes: Potential Mechanisms of Neurological Dysfunction in HHH Syndrome.

Authors:  Ângela Zanatta; Marília Danyelle Nunes Rodrigues; Alexandre Umpierrez Amaral; Débora Guerini Souza; André Quincozes-Santos; Moacir Wajner
Journal:  Neurochem Res       Date:  2016-05-09       Impact factor: 3.996

3.  Adult-onset presentation of a hyperornithinemia-hyperammonemia-homocitrullinuria patient without prior history of neurological complications.

Authors:  Kamer Tezcan; Kristal T Louie; Yong Qu; Jorge Velasquez; Frank Zaldivar; Natalia Rioseco-Camacho; José Angel Camacho
Journal:  JIMD Rep       Date:  2011-09-22

4.  Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome in adulthood: a rare recognizable condition.

Authors:  Massimiliano Filosto; Antonella Alberici; Alessandra Tessa; Alessandro Padovani; Filippo M Santorelli
Journal:  Neurol Sci       Date:  2012-12-18       Impact factor: 3.307

5.  Substrate specificity of the two mitochondrial ornithine carriers can be swapped by single mutation in substrate binding site.

Authors:  Magnus Monné; Daniela Valeria Miniero; Lucia Daddabbo; Alan J Robinson; Edmund R S Kunji; Ferdinando Palmieri
Journal:  J Biol Chem       Date:  2012-01-19       Impact factor: 5.157

6.  Ornithine In Vivo Administration Disrupts Redox Homeostasis and Decreases Synaptic Na(+), K (+)-ATPase Activity in Cerebellum of Adolescent Rats: Implications for the Pathogenesis of Hyperornithinemia-Hyperammonemia-Homocitrullinuria (HHH) Syndrome.

Authors:  Ângela Zanatta; Carolina Maso Viegas; Fernanda Hermes Hickmann; Wagner de Oliveira Monteiro; Angela Sitta; Daniela de Moura Coelho; Carmen Regla Vargas; Guilhian Leipnitz; Moacir Wajner
Journal:  Cell Mol Neurobiol       Date:  2015-03-13       Impact factor: 5.046

7.  Frequency of MELAS main mutation in a phenotype-targeted young ischemic stroke patient population.

Authors:  Turgut Tatlisumak; Jukka Putaala; Markus Innilä; Christian Enzinger; Tiina M Metso; Sami Curtze; Bettina von Sarnowski; Alexandre Amaral-Silva; Gerhard Jan Jungehulsing; Christian Tanislav; Vincent Thijs; Arndt Rolfs; Bo Norrving; Franz Fazekas; Anu Suomalainen; Edwin H Kolodny
Journal:  J Neurol       Date:  2015-11-14       Impact factor: 4.849

8.  Impairment of brain redox homeostasis caused by the major metabolites accumulating in hyperornithinemia-hyperammonemia-homocitrullinuria syndrome in vivo.

Authors:  Carolina Maso Viegas; Anelise Miotti Tonin; Angela Zanatta; Bianca Seminotti; Estela Natacha Brandt Busanello; Carolina Gonçalves Fernandes; Alana Pimentel Moura; Guilhian Leipnitz; Moacir Wajner
Journal:  Metab Brain Dis       Date:  2012-07-15       Impact factor: 3.584

Review 9.  Suggested guidelines for the diagnosis and management of urea cycle disorders.

Authors:  Johannes Häberle; Nathalie Boddaert; Alberto Burlina; Anupam Chakrapani; Marjorie Dixon; Martina Huemer; Daniela Karall; Diego Martinelli; Pablo Sanjurjo Crespo; René Santer; Aude Servais; Vassili Valayannopoulos; Martin Lindner; Vicente Rubio; Carlo Dionisi-Vici
Journal:  Orphanet J Rare Dis       Date:  2012-05-29       Impact factor: 4.123

10.  Role of early management of hyperornithinaemia-hyperammonaemia-homocitrullinuria syndrome in pregnancy.

Authors:  Matthew James Billingham; Rania Rizk
Journal:  BMJ Case Rep       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.